Cytokinetics, Inc. : Cytokinetics and Astellas Announce Collaboration in the Field of Skeletal Muscle Activation

 Cytokinetics, Inc. : Cytokinetics and Astellas Announce Collaboration in the
                     Field of Skeletal Muscle Activation

                                      


   Collaboration Will Focus on Expanding the New Frontier of Muscle Biology

 Cytokinetics is Eligible to Receive Over $40 Million During the Initial Two
 Years in Addition to Over $450 Million in Potential Milestone Payments plus
                                  Royalties

South San Francisco, CA, and Tokyo,June 25, 2013 - Cytokinetics,  Incorporated 
(NASDAQ:CYTK)  and  Astellas   Pharma  Inc.  (Tokyo   Stock  Exchange:   4503, 
"Astellas")  announced  today  a   collaboration  focused  on  the   research, 
development and commercialization of skeletal muscle activators. The  primary 
objective of the collaboration is to advance novel therapies for diseases  and 
medical conditions associated with muscle weakness. The parties will  jointly 
conduct research in  the area  of skeletal muscle  activation. Astellas  will 
have the exclusive rights  to develop and  commercialize drug candidates  that 
may arise from these activities, subject to certain Cytokinetics'  development 
and commercialization rights. In addition, Cytokinetics has granted  Astellas 
an exclusive  license  to  co-develop  and  commercialize  Cytokinetics'  drug 
candidate CK-2127107 in certain indications. 

In this collaboration, Cytokinetics will combine its foremost position in  the 
discovery and mechanistic  biology of  small molecule  activators of  skeletal 
muscle  contractility  with   Astellas'  advanced  pharmaceutical   discovery, 
development,  and   commercialization   capabilities.  During   the   two-year 
collaborative research term,  the companies will  focus on expanding  emerging 
opportunities in  skeletal muscle  contractility and  will together  identify, 
characterize,  and  optimize  fast  skeletal  troponin  activators  and  other 
potential novel  mechanism skeletal  muscle  activators. The  joint  research 
program is designed to leverage  the two companies' cutting-edge  capabilities 
in  discovery   technologies,  medicinal   chemistry,  analytical   chemistry, 
structural biology, computational  chemistry, and the  pharmacology of  muscle 
contractility. 

"We are pleased  to enter into  this collaboration with  Astellas, which  will 
enable us  to expand  our research  and development  in the  area of  skeletal 
muscle  activators,"  stated  Cytokinetics'  President  and  Chief   Executive 
Officer, Robert I.  Blum. "Through  this collaboration, we  intend to  jointly 
investigate the potential role that  CK-2127107 and follow-on skeletal  muscle 
activators can  play in  providing functional  improvements in  patients  with 
diseases characterized by muscle weakness and fatigue. We are impressed  with 
Astellas' strategic vision and  capabilities in the  areas of novel  mechanism 
biopharmaceutical research and development."

"We are excited to work with Cytokinetics to expand the new frontier of muscle
biology related to the very innovative mechanism of action of skeletal  muscle 
activation,"  stated  Yoshihiko  Hatanaka,   Astellas'  President  and   Chief 
Executive Officer. "This  new collaboration  illustrates Astellas'  important 
commitment to enhance its abilities to generate innovative drugs by  deploying 
cutting-edge science, accessing  distinguished internal  and external  talent, 
and utilizing the optimal research environment."

Under the collaboration, Cytokinetics has exclusively licensed to Astellas the
rights to co-develop  and commercialize CK-2127107,  a fast skeletal  troponin 
activator drug  candidate,  for  potential  application  in  non-neuromuscular 
indications. CK-2127107, which is currently in Phase I clinical  development, 
will be developed jointly by Cytokinetics and Astellas. Under the  agreement, 
Cytokinetics will be primarily responsible for the conduct of Phase I clinical
trials and certain Phase II  readiness activities for CK-2127107 and  Astellas 
will be primarily responsible  for the conduct  of subsequent development  and 
commercialization activities  for CK-2127107.  Astellas will  have  exclusive 
rights to develop and commercialize other fast skeletal troponin activators in
non-neuromuscular indications  and to  develop and  commercialize other  novel 
mechanism skeletal muscle  activators in all  indications, subject to  certain 
Cytokinetics'  development   and   commercialization  rights.   Outside   the 
collaboration, Cytokinetics will continue to independently develop tirasemtiv,
a fast skeletal troponin activator currently in Phase II clinical trials,  for 
the  potential   treatment  of   amyotrophic  lateral   sclerosis  and   other 
neuromuscular disorders.

Cytokinetics is eligible to receive over $40 million in the form of an upfront
payment and  reimbursement of  sponsored research  and development  activities 
during the initial two years of the collaboration. In addition,  Cytokinetics 
is  eligible  to  receive  over  $450  million  in  pre-commercialization  and 
commercialization milestones plus royalties. The parties will jointly conduct
research  to  identify  next-generation  skeletal  muscle  activators  to   be 
nominated as drug candidates. Astellas will be responsible for the activities
and  costs  associated  with   the  development  of  collaboration   products. 
Cytokinetics retains an option to conduct early-stage development for certain
agreed indications  at  its  initial  expense,  subject  to  reimbursement  if 
development  continues  under  the  collaboration.  Astellas  will  have  the 
exclusive right to commercialize collaboration products worldwide, subject  to 
Cytokinetics' option to co-promote collaboration products in the United States
and Canada. In  connection with  the co-promotion  activities, Astellas  will 
reimburse Cytokinetics  for certain  expenses  associated with  its  promotion 
activities.

Cytokinetics Conference Call / Webcast

Cytokinetics will host  a conference call  on Tuesday, June  25, 2013 at  8:30 
a.m. Eastern Time.  The conference  call will be  simultaneously webcast  and 
will be  accessible in  the Investor  Relations section  of Cytokinetics'  Web 
site; for further  information please  go to  www.cytokinetics.com. The  live 
audio of the conference  call is also accessible  via telephone to  investors, 
members of  the news  media and  the general  public by  dialing either  (866) 
999-2985 (CYTK) (United States and  Canada) or (706) 679-3078  (International) 
and typing in the passcode 97237344.  An archived replay of the webcast  will 
be available via Cytokinetics' Web site until July 25, 2013. The replay  will 
also be available via telephone from June 25, 2013 at 11:00 a.m. Eastern  Time 
until July 2,  2013 by dialing  (855) 859-2056 (United  States and Canada)  or 
(404) 537-3406 (International) and typing in the passcode 97237344.

About Cytokinetics

Cytokinetics is  a clinical-stage  biopharmaceutical  company focused  on  the 
discovery and development of novel  small molecule therapeutics that  modulate 
muscle function  for the  potential treatment  of serious  diseases and  other 
medical conditions. Cytokinetics  currently has three  compounds in  clinical 
development: omecamtiv  mecarbil  in Phase  II  for acute  and  chronic  heart 
failure,  tirasemtiv  in  Phase  II  for  amyotrophic  lateral  sclerosis  and 
CK-212107 in a Phase I study in healthy volunteers. All of the company's  drug 
candidates have  arisen from  Cytokinetics'  muscle biology  focused  research 
activities and are directed  towards the cytoskeleton.  The cytoskeleton is  a 
complex biological infrastructure that plays  a fundamental role within  every 
human cell.  Additional information  about Cytokinetics  can be  obtained  at 
http://www.cytokinetics.com.

About Astellas

Astellas Pharma Inc.,  located in  Tokyo, Japan, is  a pharmaceutical  company 
dedicated to  improving the  health of  people around  the world  through  the 
provision  of   innovative   and  reliable   pharmaceuticals.   Astellas   has 
approximately 17,000  employees worldwide.  The organization  is committed  to 
becoming  a  global   category  leader  in   Urology,  Immunology   (including 
Transplantation)  and  Infectious  diseases,  Oncology,  Neuroscience  and  DM 
Complications and Kidney  diseases. For  more information  on Astellas  Pharma 
Inc., please visit the company website at www.astellas.com/en.

Forward-Looking Statements: Cytokinetics

This press release  contains forward-looking  statements for  purposes of  the 
Private Securities Litigation  Reform Act  of 1995  (the "Act").  Cytokinetics 
disclaims any intent or obligation to update these forward-looking statements,
and claims  the  protection  of  the Act's  Safe  Harbor  for  forward-looking 
statements. Examples  of such  statements  include, but  are not  limited  to, 
statements relating  to  Cytokinetics'  and  Astellas'  planned  research  and 
development activities;  potential  milestone payments,  royalties  and  other 
payments;  the  expected  roles  of  Cytokinetics  and  Astellas  under   the 
collaboration and in developing or commercializing drug candidates or products
subject to the collaboration;  the utility and  benefits of Cytokinetics'  and 
Astellas' respective  technical capabilities;  the indications  to be  pursued 
under the collaboration;  Cytokinetics' continued  development of  tirasemtiv; 
and the properties  and potential  benefits of  Cytokinetics' skeletal  muscle 
activators. Such statements  are based on  management's current  expectations, 
but  actual  results  may   differ  materially  due   to  various  risks   and 
uncertainties, including, but not limited to: Cytokinetics anticipates that it
will be required to conduct at least one confirmatory Phase III clinical trial
of tirasemtiv  in  ALS  patients which  will  require  significant  additional 
funding, and it may be unable to obtain such additional funding on  acceptable 
terms, if  at  all;  potential  difficulties or  delays  in  the  development, 
testing, regulatory approvals for  trial commencement, progression or  product 
sale or manufacturing,  or production  of Cytokinetics'  drug candidates  that 
could slow  or prevent  clinical development  or product  approval,  including 
risks that current and past results of clinical trials or preclinical  studies 
may not be indicative  of future clinical  trials results, patient  enrollment 
for or conduct of clinical trials  may be difficult or delayed,  Cytokinetics' 
drug candidates  may  have  adverse side  effects  or  inadequate  therapeutic 
efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies
may delay or limit Cytokinetics' or its partners' ability to conduct  clinical 
trials, and Cytokinetics may be unable  to obtain or maintain patent or  trade 
secret protection  for  its  intellectual  property;  Amgen's  decisions  with 
respect to  the  design,  initiation,  conduct,  timing  and  continuation  of 
development  activities  for  omecamtiv   mecarbil;  Cytokinetics  may   incur 
unanticipated research and development and other costs or be unable to  obtain 
additional  financing  necessary  to  conduct  development  of  its  products; 
Cytokinetics may be unable to  enter into future collaboration agreements  for 
its drug candidates and programs on acceptable terms, if at all; standards  of 
care may change, rendering Cytokinetics' drug candidates obsolete; competitive
products or alternative therapies may be developed by others for the treatment
of indications Cytokinetics' drug candidates and potential drug candidates may
target; and risks  and uncertainties  relating to  the timing  and receipt  of 
payments from  its  partners, including  milestones  and royalties  on  future 
potential product sales under Cytokinetics' collaboration agreements with such
partners. For further information regarding  these and other risks related  to 
Cytokinetics' business, investors  should consult  Cytokinetics' filings  with 
the Securities and Exchange Commission.



Forward-Looking Statements: Astellas

This press release  includes forward-looking statements  based on  assumptions 
and beliefs in light of the information currently available to management  and 
subject to  significant risks  and uncertainties.  Forward-looking  statements 
include all statements  other than  statements of  historical fact,  including 
plans, strategies and  expectations for the  future, statements regarding  the 
expected timing  of filings  and approvals  relating to  the transaction,  the 
expected timing of the completion of the transaction, the ability to  complete 
the transaction or to satisfy the various closing conditions, future  revenues 
and profitability from  or growth  or any  assumptions underlying  any of  the 
foregoing.  Statements  made  in  the   future  tense,  and  words  such   as 
"anticipate," "expect," "project," "continue," "believe," "plan,"  "estimate," 
"pro  forma,"   "intend,"  "potential,"   "target,"  "forecast,"   "guidance," 
"outlook," "seek," "assume," "will," "may," "should," and similar  expressions 
are  intended  to  qualify  as  forward-looking  statements.   Forward-looking 
statements are based on estimates and assumptions made by management that  are 
believed to be reasonable, though they are inherently uncertain and  difficult 
to predict. Investors and security holders  are cautioned not to place  undue 
reliance on these forward-looking statements.



Actual financial  results  may differ  materially  depending on  a  number  of 
factors  including  adverse  economic   conditions,  currency  exchange   rate 
fluctuations, adverse legislative and  regulatory developments, delays in  new 
product launch, pricing and product initiatives of competitors, the  inability 
of the company to market existing and new products effectively,  interruptions 
in production, infringements of the company's intellectual property rights and
the  adverse  outcome  of  material  litigation.This  press  release  contains 
information on pharmaceuticals  (including compounds  under development),  but 
this information is not intended to make any representations or advertisements
regarding the efficacy or effectiveness  of these pharmaceuticals nor  provide 
medical advice of any kind. 

Contact:

Cytokinetics, Inc.
Joanna L. Goldstein (Investors & Media)
(650) 624-3000



Astellas Pharma Inc.
Corporate Communications
Tel: +81-3-3244-3201 
Fax: +81-3-5201-7473

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
HUG#1711726
 
Press spacebar to pause and continue. Press esc to stop.